

Serial No. 09/900,575  
Filed: 6 July 2001

#### REMARKS

Claims 1-3 and 10 are under examination and have been rejected.

Applicant's agent conducted a telephone interview with the Examiner on 19 November 2003 at which time claims 1 to 3 and 10 were discussed.

In response to the Examiner's suggestion, claim 1 was amended to recite functional language that does not narrow the scope of the claim, which amended language is supported throughout the specification, especially at page 9, lines 9-14, and page 11, lines 16-26, and in Example 1, pages 26-27.

Claims 2 and 3 were amended to be independent claims, with claim 2 also reciting said functional language without narrowing the scope of the claim. The amendment to claim 2 to recite residues 1 to 186 is supported in the application at page 8, lines 13-15. Claim 2 was amended to delete the term "immunogenic" from polypeptide in view of the added functional language.

Claim 10 was amended to eliminate the "immunogenic" language in view of the amendments to claims 1, 2 and 3. Claim 10 was further amended to replace "pharmacological" with "pharmaceutical" and is supported in the application at page 13, lines 14-21, which describes pharmaceutical carriers useful with the invention.

In view of these amendments, Applicant believes that claims 1-3 and 10 are in condition for allowance.

The Commissioner is authorized to charge any and all additional fees to Deposit Account No. 03-0678.

2003-11-19 22:57 From: Carella, Byrne, Bain, & Gilfillan

T-943 P.009/009 F-723

Serial No. 09/900,575

Filed: 6 July 2001

**VIA FACSIMILE**

I hereby certify that this  
correspondence is being telefaxed to  
the Examiner on the below-given date:

  
Alan J. Grant, Esq.      11/20/03  
Date

Respectfully submitted,



Alan J. Grant, Esq.

Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,  
CECCHI, STEWART & OLSTEIN

Six Becker Farm Road

Roseland, NJ 07068

Phone: 973-994-1700

Fax: 973-994-1744